REGULATED PRESS RELEASE published on 09/15/2025 at 07:00, 4 months 16 days ago Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners Biophytis secures public funding in Brazil for Obesity Phase 2 trial and signs agreements with leading local clinical partners, strengthening its OBA Phase 2 program and obtaining non-dilutive funding support through EMBRAPII Biophytis Public Funding EMBRAPII Obesity Phase 2 Trial Clinical Partners
REGULATED PRESS RELEASE published on 09/15/2025 at 07:00, 4 months 16 days ago Biophytis obtient un financement public au Brésil pour l’essai de Phase 2 dans l’obésité et signe des accords avec des centres cliniques locaux de premier plan Biophytis obtient un financement public et signe des accords pour l'essai de Phase 2 dans l'obésité au Brésil, renforçant ainsi son programme et sa valeur pour les investisseurs Biophytis Brésil Phase 2 Obésité Financement Public
BRIEF published on 09/11/2025 at 07:05, 4 months 20 days ago Biophytis Announces Phase 3 Sarcopenia Trial for BIO101 in Europe and Asia Age-related Diseases BIO101 Sarcopenia Clinical Trial Biophytis Strategy Asia And Europe
BRIEF published on 09/11/2025 at 07:05, 4 months 20 days ago Biophytis Lance un Essai de Phase 3 sur la Sarcopénie avec BIO101 Biophytis Essai Clinique Sarcopénie BIO101 Europe Et Asie
REGULATED PRESS RELEASE published on 09/11/2025 at 07:00, 4 months 20 days ago Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia Biophytis announces Phase 3 Sarcopenia Trial Strategy with BIO101 targeting age-related sarcopenia in Europe and Asia, aiming to address a significant unmet medical need and commercial market Biophytis Clinical Trial Sarcopenia Phase 3 BIO101
REGULATED PRESS RELEASE published on 09/11/2025 at 07:00, 4 months 20 days ago Biophytis dévoile sa stratégie d’essai de phase 3 dans la sarcopénie avec BIO101 en Europe et en Asie Biophytis annonce sa stratégie d'essai de phase 3 pour la sarcopénie avec BIO101 en Europe et en Asie, ciblant un marché médical important et non satisfait Biophytis Europe Asie Sarcopénie Phase 3
PRESS RELEASE published on 09/11/2025 at 06:59, 4 months 20 days ago Biophytis dévoile sa stratégie d’essai de phase 3 dans la sarcopénie avec BIO101 en Europe et en Asie Biophytis présente sa stratégie d'essai de phase 3 pour la sarcopénie avec BIO101 en Europe et Asie, visant à devenir pionnier dans ce domaine thérapeutique en croissance rapide Biophytis Essai Clinique Sarcopénie Phase 3 BIO101
BRIEF published on 09/03/2025 at 07:05, 4 months 28 days ago Biophytis obtient l'approbation de l'EMA pour une étude clinique phase 2 sur l'obésité Biophytis Essai Clinique Phase 2 Obésité EMA
BRIEF published on 09/03/2025 at 07:05, 4 months 28 days ago Biophytis Advances Obesity Treatment with EMA Approval Biophytis Obesity Treatment Clinical Trial BIO101 EMA Authorization
REGULATED PRESS RELEASE published on 09/03/2025 at 07:00, 4 months 28 days ago Biophytis obtient l'autorisation de l'EMA pour le lancement de son étude clinique de phase 2 dans l’obésité Biophytis obtient l'autorisation de l'EMA pour lancer l'étude clinique de phase 2 sur l'obésité en Europe et prépare le recrutement des patients. La société se réjouit de cette avancée réglementaire cruciale Biophytis Étude Clinique Obésité Autorisation EMA
Published on 01/31/2026 at 03:15, 5 hours 48 minutes ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 6 hours 43 minutes ago Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 7 hours 23 minutes ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 10 hours 3 minutes ago Avidian Gold Corp. Announces Director Resignation
Published on 01/31/2026 at 02:45, 6 hours 18 minutes ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 11 hours 3 minutes ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 12 hours 53 minutes ago Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 12 hours 53 minutes ago Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 12 hours 56 minutes ago Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 18:40, 14 hours 23 minutes ago ICADE - Bilan semestriel du contrat de liquidite
Published on 01/30/2026 at 17:45, 15 hours 18 minutes ago Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 17:45, 15 hours 18 minutes ago Schneider Electric lance une augmentation de capital réservée aux salariés
Published on 01/30/2026 at 08:30, 1 day ago Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés